Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The Hazards of Hazardous Drug Labeling: Time to Revisit Hydroxyurea?
source: The Hematologist
year: 2019
authors: Andrea Cervi, MD, MSc; Artemis Diamantouros, BScPhm, MEd, PhD; Madeleine Verhovsek, MD, FRCPC
summary/abstract:Despite benefits in reducing pain crises, transfusions, hospitalizations, and mortality in sickle cell disease (SCD),1-5 hydroxyurea (HU) is underutilized.1,6,7 A recent Cochrane meta-analysis found no significant increase in adverse events among HU-treated patients with SCD,8 yet fears of possible adverse effects have been identified as a key barrier to HU acceptance.9-11 In light of the poor uptake of HU among the SCD population, hematologists need to fully understand patient and provider reluctance about this disease-modifying therapy.
organization: McMaster University, Canada; University of Toronto, Canadafull text
+myBinderRelated Content
-
Sickle-Cell Patients See Hope in CRISPRSickle-cell disease is one of the most c...
-
Virtual Reality Helps Reduce Pain Among Patients With Sickle Cell DiseaseImmersive virtual reality appeared effec...
-
Marijuana use common in sickle cell patients, highlighting need for more research, study showsMany sickle cell disease (SCD)...
-
Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic sy...The risk and clinical significance of ca...
-
MARAC Statement: Health Insurance Coverage for Hematopoietic Stem Cell Transplant for Sickle Cell Disease from HLA-m...Hematopoietic stem cell transplant for s...
-
Treatment Advances in Sickle Cell Disease, Amber M. Yates, MDhttps://www.youtube.com/watch?v=oFIOKC4r...
-
Crizanlizumab 5.0 mg/kg increased the time to first on-treatment sickle cell pain crisis (SCPC) and the likelihood o...Background: In the 52-week SUSTAIN stud...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.